The Case for Periadjuvant Therapy in Early-stage Lung Cancer

Therapeutic nihilism remains a pervasive feature of lung cancer care despite remarkable advances. Regional and distant failures after seemingly curative resection are well-recognized features of lung cancer treatment, yet the appetite of both physicians and their patients for supplementary systemic cytotoxic therapy after surgery for stage I lung cancer remains low.1 Phase III studies have failed to show a major benefit for this class of...